Jardiance (Empagliflozin) Adolescent Safety in Ages 12 to 17

Why the FDA Approved Empagliflozin for Adolescents

The FDA granted approval for empagliflozin in patients aged 10 and older with type 2 diabetes in April 2023, following submission of a dedicated pediatric dataset to satisfy the Pediatric Research Equity Act requirement. This approval reflected the worsening epidemic of adolescent type 2 diabetes in the United States, where CDC data show prevalence increased by approximately 95% between 2001 and 2017 among youth [1].

The Burden of Adolescent Type 2 Diabetes

Adolescent-onset type 2 diabetes is biologically more aggressive than adult-onset disease. Beta-cell function declines faster, and pharmacotherapy that works reliably in adults sometimes shows attenuated glycemic response in teenagers. The TODAY2 study, a long-term follow-up of youth with type 2 diabetes, documented cumulative complication rates approaching those seen after decades of adult disease, underscoring the need for effective oral agents [2].

Metformin and lifestyle modification remain first-line per the American Diabetes Association's 2024 Standards of Care [3]. Empagliflozin now occupies a second-line or add-on position for adolescents whose HbA1c remains above target despite metformin, offering a non-insulin oral option with a distinct mechanism.

Mechanism Relevant to Adolescent Physiology

Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing glucosuria regardless of insulin secretion. This insulin-independent mechanism is pharmacologically appealing in adolescents who already show significant insulin resistance. Because the drug works at the kidney, its glucose-lowering effect depends on an adequate glomerular filtration rate, which is normally strong in healthy teenagers [4].

Pediatric Clinical Trial Data

The phase III pediatric trial of empagliflozin enrolled 157 patients aged 10 to 17 with type 2 diabetes inadequately controlled on metformin, insulin, or both. After 24 weeks of treatment, empagliflozin 10 mg produced a placebo-adjusted HbA1c reduction of 0.84 percentage points (P<0.001) [5]. The 25 mg dose produced a reduction of 0.94 percentage points.

Primary Efficacy Findings

Body weight declined by a placebo-adjusted 1.6 kg with the 10 mg dose at 24 weeks, a clinically meaningful finding given that excess adiposity drives insulin resistance in this population [5]. Fasting plasma glucose fell by 22 mg/dL compared to placebo.

These effects are modest compared to what GLP-1 receptor agonists produce in adolescents, but empagliflozin is an oral tablet taken once daily, which matters considerably for adherence in teenagers.

Safety Profile in the 52-Week Extension

The 52-week extension of the pediatric trial provides the longest available safety window specific to this age group. The overall adverse event rate was 72.6% with empagliflozin versus 66.1% with placebo, a difference driven largely by genital mycotic infections and urinary tract infections rather than serious events [5].

Serious adverse events occurred in 5.8% of empagliflozin-treated patients versus 8.1% of placebo-treated patients, suggesting no excess serious harm signal at one year. No deaths were reported in the pediatric trial.

Diabetic Ketoacidosis Risk in Adolescents

DKA is the most serious class-level risk of SGLT2 inhibitors, and adolescents may be at higher absolute risk than adults for several reasons. Euglycemic DKA, the form most often triggered by SGLT2 inhibitors, can be missed because blood glucose may remain below 250 mg/dL while ketoacidosis develops [6].

Why Adolescents May Be More Vulnerable

Adolescents with type 2 diabetes frequently have overlapping features with type 1 disease, including low or absent C-peptide in some cases, autoantibody positivity in approximately 10 to 15%, and greater beta-cell stress from obesity-related glucotoxicity [7]. A patient with unrecognized autoimmune diabetes misclassified as type 2 who receives an SGLT2 inhibitor faces a substantially elevated DKA risk.

The FDA prescribing information for empagliflozin carries a warning to assess patients for type 1 diabetes before initiating therapy and to discontinue the drug if DKA is suspected [8]. The ADA recommends measuring fasting C-peptide and diabetes-related autoantibodies (GAD65, IA-2, ZnT8) before starting an SGLT2 inhibitor in any adolescent with type 2 diabetes [3].

Perioperative and Illness Management

Adolescents must hold empagliflozin at least 3 to 4 days before elective surgery, consistent with the joint guidance from the American Society of Anesthesiologists [9]. During intercurrent illness with reduced oral intake, vomiting, or fever, the drug should be stopped and ketones checked. This "sick-day rule" needs clear written instructions given to both the patient and parent or caregiver.

A practical pre-prescription checklist for empagliflozin in adolescents should include: confirm type 2 diabetes diagnosis with C-peptide ≥0.6 nmol/L, check GAD65 autoantibodies, verify eGFR ≥45 mL/min/1.73m², educate on sick-day rules with a written action plan, provide urine ketone strips or a blood ketone meter, and schedule a 4-week follow-up call.

Genital Mycotic Infections

Glucosuria creates a glucose-rich environment in the perineum, promoting yeast overgrowth. In the pediatric trial, genital mycotic infections occurred in approximately 9% of empagliflozin-treated females versus 2% of placebo-treated females [5]. In males, the rate was lower at approximately 3% versus 0%.

Managing Infections in Adolescent Patients

Clinicians should counsel adolescent females specifically about signs of vulvovaginal candidiasis before starting therapy. A single dose of oral fluconazole 150 mg resolves most episodes. Persistent or recurrent infections should prompt a review of glycemic control, hygiene practices, and whether to continue the drug.

Adolescents may feel embarrassed reporting genital symptoms. Proactive, nonjudgmental questioning at follow-up visits improves detection. The FDA label notes that patients with a history of recurrent genital infections may have a higher baseline risk [8].

Urinary Tract Infections

Urinary tract infections occurred in 6.3% of empagliflozin-treated adolescents versus 4.8% of placebo-treated patients in the pediatric trial [5]. The absolute difference is small, but UTIs in adolescent females already carry a baseline prevalence of approximately 8% annually, so the incremental burden is real [10].

Urosepsis and pyelonephritis are rare but documented in adult post-marketing data. Adolescents should be counseled to report dysuria or fever promptly. Standard antibiotic treatment applies; empagliflozin does not need to be permanently discontinued for uncomplicated UTI.

Hypoglycemia Risk

Empagliflozin does not cause hypoglycemia when used as monotherapy because glucosuria stops once blood glucose normalizes. The risk emerges when empagliflozin is combined with insulin or a sulfonylurea. In the pediatric trial, symptomatic hypoglycemia occurred in 5.8% of empagliflozin-treated patients who were on background insulin, compared to 3.2% with placebo [5].

Insulin doses may need to be reduced by 10 to 20% when initiating empagliflozin, consistent with the prescribing information recommendation [8]. Adolescents on insulin who start empagliflozin need a structured glucose monitoring plan and clear hypoglycemia action steps.

Blood Pressure and Volume Effects

Empagliflozin produces osmotic diuresis and a modest natriuretic effect, reducing systolic blood pressure by approximately 3 to 4 mmHg in adults [11]. In adolescents, the pediatric trial reported a placebo-adjusted systolic reduction of 2.9 mmHg at 24 weeks [5].

Orthostatic Symptoms in Teenagers

Adolescents who are already volume-depleted from illness, heat exposure during sports, or poor fluid intake may experience symptomatic hypotension or dizziness. Athletes using empagliflozin should increase fluid intake during training. Coaches and athletic trainers should be informed that the medication has a mild diuretic effect.

Volume-related adverse events were reported in 1.3% of the empagliflozin group versus 0% of the placebo group in the pediatric trial, a numerically small but clinically relevant difference in an active population [5].

Renal Considerations in Adolescents

The recommended minimum eGFR for initiating empagliflozin for glycemic control is 45 mL/min/1.73m², per the FDA label [8]. Adolescents with obesity-related nephropathy, a growing concern given the prevalence of metabolic syndrome in youth, may present with early renal impairment that should be assessed before prescribing.

Renal Protective Signals

In adults, empagliflozin reduced the risk of progression to end-stage renal disease in the EMPA-KIDNEY trial (N=6,609), which showed a 28% relative risk reduction in the composite of kidney disease progression or cardiovascular death (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) [12]. Whether this renal protection extends to adolescents with early diabetic nephropathy is not yet established, but the mechanistic basis, reduction in intraglomerular pressure, applies equally to younger kidneys.

Serum creatinine and eGFR should be checked at baseline and at 3 months after starting therapy. A transient 5 to 10% drop in eGFR in the first weeks of treatment is expected and is not a reason to stop the drug [8].

Growth and Bone Density Monitoring

Growth Velocity Data

Height velocity was a pre-specified secondary endpoint in the 52-week pediatric extension. The mean height velocity was 5.2 cm per year with empagliflozin versus 5.4 cm per year with placebo, a difference of 0.2 cm per year that did not reach statistical significance [5]. This provides modest reassurance but cannot rule out small effects on linear growth over multi-year exposure.

Plotting height on a growth chart at every visit remains standard practice for any adolescent on a chronic medication. Deviations from expected growth trajectory should prompt an endocrine review.

Bone Density

SGLT2 inhibitors have been associated with increased fracture risk in adults, particularly canagliflozin, which carries an FDA fracture warning [13]. Empagliflozin showed no significant fracture signal in EMPA-REG OUTCOME (N=7,020 adults) over a median 3.1 years [14]. Pediatric-specific bone density data from DXA scanning are not yet available for empagliflozin.

Adolescence is a critical window for bone mineral accrual. The American Academy of Pediatrics recommends optimizing calcium (1,300 mg/day) and vitamin D (600 IU/day) intake in all adolescents [15]. Clinicians should document fracture history, calcium intake, and physical activity at baseline.

Cardiovascular Safety in the Pediatric Context

The landmark EMPA-REG OUTCOME trial enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Empagliflozin reduced the rate of major adverse cardiovascular events by 14% (hazard ratio 0.86, 95% CI 0.74 to 0.99, P=0.04 for superiority) and cardiovascular death by 38% (hazard ratio 0.62, 95% CI 0.49 to 0.77) compared to placebo over a median 3.1 years [14].

Adolescents do not yet have established cardiovascular disease, so the cardiovascular mortality benefit documented in EMPA-REG OUTCOME does not directly translate to this age group. Subclinical atherosclerosis begins in adolescence, however, and early glycemic control reduces long-term vascular risk. The ADA 2024 Standards of Care state: "Youth with type 2 diabetes have a high lifetime risk of microvascular and macrovascular complications and should receive comprehensive cardiovascular risk reduction" [3].

Mental Health and Adherence Considerations

Adolescents with type 2 diabetes carry a disproportionate burden of depression and anxiety. A systematic review published in Diabetes Care (2018) found depression prevalence of 15 to 22% in youth with type 2 diabetes versus 7% in the general adolescent population [16]. Untreated depression is a major driver of medication non-adherence.

Empagliflozin's once-daily oral dosing is simpler than insulin regimens, which may support adherence. There is no published pharmacokinetic or pharmacodynamic interaction between empagliflozin and common adolescent psychotropic medications (SSRIs, SNRIs), but clinicians should review the full medication list for any CYP3A4-mediated interactions.

Mental health screening using a validated tool such as the PHQ-A (Patient Health Questionnaire for Adolescents) at every quarterly visit is recommended by the ADA for all youth with type 2 diabetes [3].

Drug Interactions Relevant to Adolescents

Empagliflozin is a substrate of UGT1A3, UGT1A8, UGT1A9, and UGT2B7. Rifampin reduces empagliflozin AUC by approximately 35%, which may reduce efficacy [8]. Diuretics used for other conditions such as hypertension can potentiate volume depletion. Non-steroidal anti-inflammatory drugs (NSAIDs), commonly used by adolescent athletes, may attenuate the renal hemodynamic benefits and should be minimized.

Oral contraceptives do not appear to alter empagliflozin pharmacokinetics based on adult crossover studies [8]. This is relevant for adolescent females who may be co-prescribed hormonal contraception.

Dosing and Administration for Adolescents Ages 12 to 17

The approved starting dose for patients aged 10 and older with type 2 diabetes is 10 mg once daily taken in the morning, with or without food. After a minimum of 12 weeks on the 10 mg dose, clinicians may increase to 25 mg once daily if additional glycemic control is needed and the drug is tolerated [8].

Practical Titration Guidance

Twelve weeks at the starting dose allows time to assess tolerability, genital infection occurrence, and blood pressure response before escalating. An HbA1c check at 12 weeks informs whether escalation is warranted. If HbA1c remains above 8.0% despite 10 mg, and the patient has no volume-related complaints, advancing to 25 mg is reasonable.

Tablets should not be crushed or split. For adolescents who have difficulty swallowing tablets, no suspension formulation is currently FDA-approved. The 10 mg tablet size is comparable to a standard vitamin supplement.

Monitoring Schedule

At baseline: HbA1c, fasting glucose, eGFR, urinalysis, C-peptide, GAD65 antibody, blood pressure, height, weight, BMI percentile. At 4 weeks: blood pressure, symptoms of UTI or genital infection, adherence check. At 12 weeks: HbA1c, eGFR, weight, blood pressure, genital/UTI symptoms, dose escalation decision. Every 3 months thereafter: HbA1c, weight, blood pressure, height (plotted on growth chart), mental health screen with PHQ-A. At 12 months: eGFR, fasting lipids, urine albumin-to-creatinine ratio.

Special Populations Within the Adolescent Age Group

Adolescents With Obesity

Obesity prevalence among U.S. Adolescents reached 20.3% in the 2017 to 2020 NHANES cycle [17]. Empagliflozin produces modest weight loss averaging 1.5 to 2.5 kg in adults over 24 weeks, driven by caloric loss through glucosuria rather than appetite suppression [11]. In adolescents in the pediatric trial, the 1.6 kg placebo-adjusted weight loss at 24 weeks is clinically useful but not sufficient as a primary obesity treatment [5].

Adolescents with a BMI above the 95th percentile who require more substantial weight loss may need concurrent GLP-1 receptor agonist therapy. Liraglutide is FDA-approved for obesity in patients aged 12 and older, and semaglutide 2.4 mg is approved for adolescent obesity, providing an option that can be combined with empagliflozin when both glycemic control and weight reduction are primary goals [18].

Adolescents With Chronic Kidney Disease

Empagliflozin is not recommended for glycemic control when eGFR falls below 45 mL/min/1.73m² [8]. Adolescents with diabetic nephropathy presenting with eGFR in the 30 to 44 range should be managed with endocrinology and nephrology co-management. Once eGFR drops below 30, the drug is contraindicated for glycemic indications.

Patient and Family Education Priorities

Parents and adolescents need plain-language education on four topics before the first prescription is dispensed. First: urine will contain glucose by design, so a positive urine dipstick for glucose does not mean the drug is not working. Second: any vomiting, abdominal pain, or difficulty breathing warrants same-day contact with the care team to check ketones. Third: genital itching or discharge should be reported at the next visit without embarrassment. Fourth: the medication must be paused before planned surgery or prolonged fasting.

Written sick-day rules, a ketone-checking tutorial (blood meter preferred over urine strips for sensitivity), and an after-hours contact number should accompany the first prescription. The Endocrine Society clinical practice guidelines on SGLT2 inhibitors recommend structured patient education as a prerequisite for safe prescribing [19].